股票代码：003020 股票简称：立方制药 合肥立方制药股份有限公司投资者关系活动记录表 编号：2025-001 | 投资者关系活动类 | □特定对象调研 □分析师会议 | | --- | --- | | 别 | □媒体采访 √业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及人 | 线上参与立方制药 2024 年年度网上业绩说明会的投资 | | 员姓名 | 者 | | 时间 | 2025 年 04 月 29 日（星期二）下午 15:00-16:30 | | 地点 | "约调研"微信小程序 | | 上市公司接待人员 | 董事长：季俊虬先生 | | 姓名 | 副董事长：邓晓娟女士 | | | 总经理：崔欢喜先生 | | | 独立董事：杨模荣先生 | | | 副总经理、董事会秘书：夏军先生 | | | 财务总监：勾绍兵先生 1、从年报可知，公司医药工业板块表现亮眼，实现 | | | 营业收入 亿元，同比增长 18.92%，像益气和胃胶 13.77 | | | 囊、盐酸羟考酮缓释片等产品增长显著；但整体营收却 | | | ...

Group 1 - The company, Hefei Lifan Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the registration of Paliperidone Extended-Release Tablets (6mg, 3mg) [1][2] - The drug is classified as a new antipsychotic medication with strong control effects, high affinity, tolerability, and efficacy, designed to release active ingredients slowly for stable blood concentration [2] - Paliperidone Extended-Release Tablets are indicated for the treatment of schizophrenia in adults and adolescents aged 12-17 years (weighing ≥29kg) [2] Group 2 - The approval of the two specifications (6mg, 3mg) will enhance the company's product pipeline in psychiatric medications and improve its market competitiveness [2] - As of the announcement date, there are two imported drug approvals and four domestic drug approvals for this medication in China, indicating a competitive landscape [2]